Post-translational polymodification of β1-tubulin regulates motor protein localization in platelet production and function

Abdullah O. Khan,1 Alexandre Slater,1 Annabel Maclachlan,1 Phillip L.R. Nicolson,1 Jeremy A. Pike,1,2 Jasmeet S. Reyat,1 Jack Yule,1,2 Rachel Stapley,1 Julie Rayes,2 Steven G. Thomas,1,2 and Neil V. Morgan1

1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham and 2The Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK

ABSTRACT

In specialized cells, the expression of specific tubulin isoforms and their subsequent post-translational modifications drive and coordinate unique morphologies and behaviors. The mechanisms by which β1-tubulin, the platelet and megakaryocyte (MK) lineage restricted tubulin isoform, drives platelet production and function remains poorly understood. We investigated the roles of two key post-translational tubulin polymodifications (polyglutamylation and polyglycylation) on these processes using a cohort of thrombocytopenic patients, human induced pluripotent stem cell derived MK, and healthy human donor platelets. We find distinct patterns of polymodification in MK and platelets, mediated by the antagonistic activities of the cell specific expression of tubulin tyrosine ligase like enzymes and cytosolic carboxypeptidase enzymes. The resulting microtubule patterning spatially regulates motor proteins to drive proplatelet formation in megakaryocytes, and the cytoskeletal reorganization required for thrombus formation. This work is the first to show a reversible system of polymodification by which different cell specific functions are achieved.

Introduction

Microtubules are large, cytoskeletal filaments vital to a host of critical functions including cell division, signaling, cargo transport, motility, and function.1,2 The question of how ubiquitously expressed filaments can facilitate complex and highly unique behaviors (such as neurotransmitter release and retinal organization) has been addressed by the concept of the tubulin code.3,4 This paradigm accounts for the specialization of microtubules and their organization by describing a mechanism in which particular cells express lineage restricted isoforms of tubulin. These cell specific isoforms are then subject to a series of post-translational modifications (PTM) which alter the mechanical properties of microtubules, and their capacity to recruit accessory proteins (e.g., motor proteins).1,2,4,5

A host of PTM have been reported in a range of cell types, including tyrosination, acetylation, glutamylation, glycylation, and phosphorylation. The loss of specific tubulin PTM has been linked to disease and dysfunction in motile and non-motile cilia (including respiratory cilia, retinal cells), spermatogenesis, muscular disorders, and neurological development.1,4,6–11 Despite an increasing understanding of the importance of tubulin PTM in disease, the role of the tubulin code in the generation of blood platelets from their progenitors, megakaryocytes (MK) remains poorly understood.

Platelets are the smallest component of peripheral blood, and circulate as anucleate cells with an archetypal discoid shape maintained by a microtubule marginal band.12,13 Antagonistic motor proteins maintain the resting state of the marginal band, and during platelet activation a motor dependent mechanism results in sliding which extends the marginal band and causes the transition to a spherical shape.13–15

Conversely MK are the largest and rarest hematopoietic cells of the bone marrow.
These cells are characteristically large, polyploid cells with unique morphological structures (e.g., the invaginated membrane system (IMS)) required to facilitate the production of thousands of blood platelets and packaged within them the required pro-thrombotic factors.16,18 MK form long, beaded extensions into the lumen of bone marrow sinuses - where these proplatelet extensions then experience fission under the flow of sinusoidal blood vessels which results in the release of barbell shaped pre-platelets and platelets into the blood stream.16

Both MK and platelets express a lineage-restricted isoform of β1-tubulin encoded by the gene TUBB1.17 In humans, TUBB1 mutations have been shown to result in impaired platelet production, with a resulting macrothrombocytopenia.18,19 More recently, a C-terminal truncation of β1-tubulin has been shown to cause a macrothrombocytopenia, suggesting that C-terminal modifications may be drivers of protein function and causative of the disease phenotype observed.20

While the loss of β1-tubulin is known to result in macrothrombocytopenia, the mechanisms by which this isoform of tubulin affects the dramatically different cytoskeletal behaviors of platelets and MK remains poorly understood. In the context of the tubulin code, MK and platelets present a particularly interesting model. Both cells express β1-tubulin, but undergo markedly different cytoskeletal changes. To date, acetylation and tyrosination have been the PTM primarily reported in MK and platelets, however neither modification is specific to the C-terminal tail encoded by TUBB1. Fiore et al. showed that a C-terminal truncation of β1-tubulin phenocopies the complete loss of the protein.21 We, therefore, hypothesize that PTM specific to the C-terminus of TUBB1 are required for the complex morphological rearrangements required for both MK and platelet function.

The C-terminal tail of β1 tubulin is particularly rich in glutamate residues which are often targeted for two key PTM implicated in human disease. Polyglutamylation and polyglycycylation are PTM which target glutamate residues on both tubulin subunits (α and β) and result in the addition of glutamate or glycine residues respectively.12,22,23 As both PTM target the same residue they are together referred to as polymodification. Polyglycycylation has been observed in microtubules in centrioles, axonemes, neuronal outgrowths, and mitotic spindles.12

To date polyglycycylation has not been reported in MK or platelets. Recently Van Dijk et al. reported on the polyglutamylation of β1 tubulin downstream of the integrin α2β 3 in a CHO cell line engineered to express TUBB1, murine MK, and platelets spread on fibrinogen.24 In our work, we report the effects of the loss of the C-terminus of β1-tubulin in patients with rare TUBB1 variants linked to the low platelet counts. Using induced pluripotent stem cell (iPSC) derived MK and CRISPR knockout (KO), we report a mechanism of polymodification which distinctly patterns β1-tubulin in MK and platelets to spatially coordinate key motors. We describe the graded, cell specific expression of enzymes which mediate this, and finally report a novel gene, TTLL10, which is associated with excessive bleeding.

Methods

Study approval

Whole blood was obtained for each experiment from healthy volunteers under the University of Birmingham’s ERN 11-0175 license ‘The regulation of activation of platelets’. The Genotyping and Phenotyping of Platelets (GAPP) study was approved by the National Research Ethics Service Committee West Midlands – Edgbaston (REC reference 06/MRE07/36). Participants gave written informed consent in compliance with the Declaration of Helsinki. The GAPP study is included in the National Institute for Health Research Non-Malignant Hematology study portfolio (ID 9858), and registered at ISRCTN (http://www.isrctn.org) as ISRCTN77951167.

Whole exome sequencing

In order to identify the possible causative variants in these families we sequenced the whole exome of the affected individuals with the SureSelect human All Exon 50 Mb kit (Agilent Technologies) and sequenced on the HiSeq 2500 (illumina) with 100 bp paired-end reads.

Stem cell culture and induced pluripotent stem cell megakaryocyte differentiation

Gibco human episomal iPSC line was purchased from Thermo Scientific and cultured on Gelretx basement membrane in StemFlex medium (Thermo Scientific). iPSC differentiation to mature, proplatelet forming MK was performed using a protocol based on work published by Feng et al.25 The IDT Alt-R-RNRNP system was used to target and knock out TUBB1. iPSC transfection was performed using Lipofectamine Stem (Life Technologies) according to the manufacturer instructions.

TUBB1 homology modeling

Homology models of TUBB1 wild-type (WT) and variants were made using SWISS MODEL software,24–26 using the solved TUBB3 heterodimer as a template PDB: 5J3Z27. TUBB1 and TUBB3 share approximately 80% sequence identity, and the model created corresponds to residues 1-425 of TUBB1. (Note that the C-terminal tail of TUBB1 is not presented in this model as there is no known or homologous structure available for this highly divergent sequence. The C-terminal portion of this model is used only as a means to visualize the effect of genetic variations on the C-terminal tail of TUBB1.)

Statistical analysis

Statistical analysis was performed using GraphPad PRISM 7. Specifics of each test are detailed in the figure legends of the relevant figures. P-values below 0.05 were considered significant.

Detailed Materials and Methods can be seen in the Online Supplementary Appendix.

Results

Identification and initial characterization of TUBB1 variants in patients with inherited thrombocytopenia and platelet dysfunction

Using whole exome sequencing and Congenica Clinical genetic variant interpretation software29 of patients recruited to the GAPP study, two C-terminal TUBB1 variants were identified in unrelated families presenting with macrothrombocytopenia (Figure 1A; Online Supplementary Figure S1). Affected individuals in family A were found to be heterozygous for an arginine to tryptophan amino acid substitution (c.1075C>T, p.R359W) in TUBB1. Individuals in this family also carry a GH1B variant (p.Cys168Phe). Variants in both genes have been linked to thrombocytopenia, however only individuals A:1 and A:3 (carrying...
TUBB1 variants), present with a macrothrombocytopenia (107x10⁹/L and 85x10⁹/L respectively). Individual A:2 carries the GFI1B variant but is WT for TUBB1 and presents with a normal platelet count (221x10⁹/L). Individuals A:1 and A:3 also present with significantly higher immature platelet fractions (IPF) and mean platelet volumes (MPV) when compared to their TUBB1 WT relatives (55.5% and 55.1% compared to 24.5%, MPV for A:1 and A:3 too large for measurement). This variation in count, IPF and platelet morphology in individuals with the R359W variant may suggest that the TUBB1 variant is linked to the macrothrombocytopenia observed.

Family/patient B was an elderly gentleman (now deceased) with a G insertion and subsequent frameshift truncation of the β1-tubulin protein 19 amino acids from the site of insertion (c.1080insG, p.L361Afs*19). This patient had a severe thrombocytopenia with a platelet count of 11x10⁹/L and an MPV above 13.4 (Figure 1B). At the time of study, IPF measurement was unavailable.

p.L361Afs*19 is absent in the latest version of the gnomad database (accessed October 2020), while p.R359W is a rare variant with a frequency of 6.75x10⁻⁶ (gnomad accessed October 2020) with a significant pathogenicity prediction score of 25.4 using combined annotation dependent depletion (CADD), where a score of greater or equal to 20 indicates the 1% most deleterious sequence variants in the genome. Both variants were analyzed using in silico bioinformatic tools and were scored as ‘uncertain significance’ based on the current ACMG guidelines (Online Supplementary Figure S1). Both TUBB1 variants are positioned towards the C-terminal region of β1-tubulin as indicated in Figure 1C and D. This region is positioned away from the dimer interface with α-tubulin, and the glutamate rich C-terminal tail, not present in the model, is an established site for PTM (Figure 1C and D). Both affected TUBB1 sequence variants are highly conserved in mammals (Figure 1E). R359 is found within a loop region towards the C-terminus of tubulin, and we predict mutating this residue would not cause dramatic misfolding within the protein secondary structure. R359 does form direct polar contacts with the N-terminal helix and removing this contact through the sequence variant to the hydrophobic tryptophan may result in minor structural changes to the connected C-terminal regions, potentially affecting PTM or interactions with critical microtubule accessory proteins (MAP) (Figure 1C and D). Similarly, the G insertion and subsequent frameshift effectively deletes the C-terminus of the protein and would therefore, if the protein folds correctly, result in effects similar, or more extreme, to the substitution of R359.

Patient B demonstrated a significant reduction in surface P-selectin expression and fibrinogen binding by flow cytometry in response to all agonists tested (Online Supplementary Figure S1). Family A showed no change in the levels of surface receptor expression, but weak P-selectin and fibrinogen responses when activated with a low concentration ADP, CRP, and PAR-1, suggesting a mild functional defect (Online Supplementary Figure S1C). Patient B also showed marked reduced expression of P-selectin and fibrinogen uptake in response to the same activation agonists (Online Supplementary Figure S1D and E). Patients with C-terminal variants in this study and others previously reported by Fiore et al. present with a macrothrombocytopenia also found in individuals with a complete loss of the β1-tubulin, suggesting that the C-terminal tail is likely critical to the function of TUBB1 in the roles of microtubules in MK and platelets. As this C-terminal tail is rich in glutamate residues which are often targeted for polymodification, we began to investigate the polymodification of β1-tubulin.

C-terminal variants of β1-tubulin fold correctly and demonstrate a reduction in polymodification

First, we investigated the effects of the two patient variants (p.R359W and p.L361Afs*19) on the folding and potential polymodification of β1-tubulin. We designed, generated, and validated a β1-tubulin-mApple fusion construct (Online Supplementary Figure S2). This plasmid was further mutated to harbor each of the patient variants (p.R359W and p.L361Afs*19), and an artificial C-terminal truncation which specifically deletes the glutamate rich C-terminal tail (Figure 2A; Online Supplementary Figure S2). The WT β1-tubulin construct was transfected into Hek293T cells and co-stained for polyglutamylated and polyglycylated tubulin specifically. Transfected cells are exclusively positive for both residues indicating that β1-tubulin is indeed polymodified (Figure 2B). Expression of each of the mutated constructs show that both patient variants and the C-terminal truncation fold correctly (Figure 2C). Furthermore each of them results in a consistent and significant reduction in polymodification (Figure 2D). This data indicates that both patient variants result in a correctly folded β1-tubulin which has a similar effect to a truncation of the C-terminus, and is further supported by western blotting of mutant constructs (Online Supplementary Figure S3) which show a significant reduction in polymodification.

Induced pluripotent stem cell-derived proplatelet forming megakaryocytes are both polyglycylated and polyglutamylated

The tubulin code posits that a highly lineage and species specific expression of modifying enzymes mediates cell specific PTM. While our transfection data successfully indicates that β1-tubulin is indeed polymodified, and that each of our patient genetic variants result in the expression of a functional β1-tubulin with a C-terminal truncation, data from both human MK and platelets is needed to dissect the role of polymodification in these cells.

To date, polyglycylation has not been reported in either platelets or MK. Polyglutamylation has recently been reported in a modified CHO cell line and human platelets. In order to investigate polymodification in human MK, we adapted a directed differentiation protocol previously reported by Feng et al. to generate large populations of mature, proplatelet forming cells (Online Supplementary Figure S4). iPSC-MK were stained for CD42b as a marker for mature, and hence TUBB1 expressing, MK, and both polyglutamylated and polyglycylated tubulin. CD42b+ cells were found to be positive for both polyglutamylated tubulin and polyglycylated tubulin (Figure 3A), while neighboring cells in the sample negative for CD42b did not demonstrate these polymodifications (Figure 3B). Across multiple differentiations we consistently yielded a purity of approximately 50-60% CD42b+ cells (Figure 3C), which on analysis are positive for both polyglutamylated and polyglycylated tubulin (Figure 3D). Finally, 100% of proplatelet forming cells observed across replicates were positive for both polymodifications (Figure 3E), and this was further confirmed by western blotting (Figure 3F).
Figure 1. Candidate TUBB1 variants and their hypothesised effect on the C-terminus of β1-tubulin. (A and B) Two unrelated families were identified as carrying genetic variations in the TUBB1 gene within six base pairs of one another. The first, family A, is comprised of three individuals, two of whom carry an arginine to tryptophan (p.R359W) coding variant. Interestingly, all three individuals in family A harbor an additional GFI1B variant. However, the individuals with the reported TUBB1 variant (A:1 and A:3) present with a macrothrombocytopenia and high immature platelet fractions (IPF), while the patient without the R359W TUBB1 variant presented with a normal platelet count. The second family is comprised of a single individual, recently deceased, with a frameshift variant six base pairs from the missense change reported in family A. In this individual’s case, the insertion of a guanine nucleotide results in a frameshift with a premature stop codon 19 amino acids from the leucine to alanine change. Platelet count normal range 147-327x10⁹/L, (n=40), mean platelet volumes (MPV) normal range 7.8-12.69 fL (n=40), immature platelet fraction (IPF) normal range 1.3-10.8% (n=40). (C) The C-terminal tail is downstream of both genetic variants in these families, and projects away from the dimer:dimer interface. The C-terminal sequence of TUBB1 is rich in glutamate residues which can be targeted for polymodification. (D) Based on homology modeling of TUBB1, we predict that the missense variant reported in family A is likely to affect the fold of the C-terminal tail, while the frameshift causes a truncation of this region. (Black arrows indicate the position of the R359 residue). (E) The arginine residue substitution in family A is highly conserved across species, as are sequences adjacent to the frameshift in patient B.
CRISPR knockout of TUBB1 results in a complete loss of proplatelet formation

To date, the loss of TUBB1 has not been studied in human MK. We generated an iPSC line with a CRISPR mediated bi-allelic loss of function mutation in the N-terminus of the coding region of TUBB1 (Figure 3G; Online Supplementary Figure S5). The mutation of the TUBB1 start codon on both alleles results in a complete loss of expression (absence of T2 band in Figure 3H) and proplatelet formation in vitro (Figure 3I and J, right panel). Unfortunately, our attempts to generate C-terminal truncations through CRISPR in iPSC-MK were unsuccessful as multiple guides targeting the 3' end of the TUBB1 gene failed to cleave the genomic sequence. Interestingly while TUBB1 KO clones stain positively for polyglutamylated and polyglycylated tubulin, the distribution of these residues is disturbed

Figure 2. Continued on following page.
when compared to WT platelet forming iPSC-MK (Figure 3K). While polyglycylated and polyglutamylated residues form a distinct peripheral band around WT MK as shown in Figure 3K, the KO cells demonstrate a diffuse tubulin staining (evidenced by line profiles in Online Supplementary Figure S7). Figure 3L shows quantification of this staining whereby WT iPSC-MK display higher mean intensity than KO constructs in polyglycylated tubulin, however no significant quantitative change in polyglutamylation was observed. This is the first data demonstrating the effects of the loss of $TUBB1$ expression in human MK.

Platelets demonstrate a different pattern of polymodification

We hypothesized that the $\beta 1$-tubulin polymodifications evident in MK might be differently regulated between resting and activated platelets. We therefore compared immunofluorescence staining of polyglutamylated and polyglycylated tubulin between resting platelets and cells spread on fibrinogen and collagen.

Resting platelets demonstrate polyglutamylated tubulin which partially co-localizes with the $\beta 1$-tubulin marginal band unlike MK which demonstrate extensive polyglycylated tubulin in proplatelet forming cells (Figure 4A). On fibrinogen and collagen spreading, polyglutamylation is evident, notably at the marginal band of spreading cells on fibrinogen (Figure 4B). A lack of polyglycylation is consistent in both resting and activated platelets. Western blotting of resting platelets and cells activated through stimulation by CRP over time does not show an increase in the total

---

Figure 2. Cells expressing wild-type and mutated $\beta 1$-tubulin demonstrate C-terminal polymodification. (A) Constructs carrying wild-type (WT), patient variants (p.R359W and p.L361As*19), and a C-terminal tail truncation of $\beta 1$-tubulin fused to the fluorescent reporter mApple at the N-terminus were designed and cloned. (B) The WT construct was first transfected into Hek293T cells, which were then fixed and immunostained for polyglutamylated and polyglycylated tubulin residues specifically. (C and D) A comparison of the WT and mutated constructs shows a reduction in polyglutamylation and polyglycylation in each mutant compared to the WT. (n=3 independent differentiations, standard deviation plotted on graphs. Two-way ANOVA with multiple comparisons performed to establish significance.)
Figure 3. Continued on following page.
Figure 3. Mature, proplatelet forming induced pluripotent stem cell megacaryocytes are both polyglutamylated and polyglycylated. TUBB1 knockout (KO) iPSC-MK do not form proplatelets and demonstrate disordered polymodified tubulin. (A) iPSC-MK co-stained for CD42 and polyglycylated or polyglutamylated tubulin show that these cells are positive for both polymodifications. Both polyglutamylated and polyglycylated tubulin are evident in proplatelet extensions, including nascent platelet swellings on the proplatelet shaft. (B) Neighboring CD42b- cells are negative for both polymodifications (indicated by red arrows). (C and D) Approximately 50-60% of cells in multiple differentiations are CD42b+, and these cells are 100% double positive for polymodification and CD42b+. (E) All proplatelet extensions observed are positive for polymodification. (F) Polyglutamylation and polyglyclylation are evident by western blotting in mature iPSC-MK derived from three separate differentiations. (G) iPSC were transfected with a TUBB1 targeting guide RNA, after which indel positive cells were isolated and sequenced to positively identify a bi-allelic insertion-deletion mutant (clone T2). (H) This clone was further analyzed and loss of β1-tubulin expression was confirmed by quantitative real-time polymerase chain reaction (qRT-PCR). (I) A comparison of proplatelet production in wild-type (WT) vs. TUBB1 KO cells revealed a complete loss of proplatelet formation in mutant CD41/42b+ cells. (K) TUBB1 KO clones show a disordered arrangement of polymodified residues when compared to WT cells, KO cells do not demonstrate the reorganization of tubulin to the periphery of the cell evident in WT iPSC-MK (indicated by red arrows). (L) A measure of the polyglycylation and polyglutamylation in WT vs. KO clones reveals a significant increase in polyglycylation in mutant cells consistent with an aberrant accumulation of these residues, (n=3 independent differentiations, standard deviation plotted on graphs).
amount of polyglutamylated tubulin (Figure 4C). An increase in the co-localization between β1-tubulin and polyglutamylated residues suggests that while the total polyglutamylation of platelets remains unchanged through activation, the distribution of these residues is altered (Figure 4D). We confirmed the polyglutamylation (and loss of polyglycylation) in microthrombi generated by CRP stimulation (Figure 4E to G). This data shows that while polyglutamylation and polyglycylation are evident in platelet producing iPSC-MK, polyglycylation is completely lost in mature platelets. This is the first evidence of a system whereby these competitive polymodifications are dramatically altered between the ‘parent’ and terminal cell, suggesting markedly different roles for these residues in mediating the function and activity of β1-tubulin. Acetylation and tyrosination have been previously reported in platelets, however, their role in maintaining the marginal band and/or driving morphological change on platelet activation remains unclear. In order to determine whether the polyglutamylation of the marginal band we observe thus far coincides with these PTM, we performed a time course of spreading on fibrinogen to determine whether there is an equivalent increase in either acetylation or tyrosination of the marginal band. Interestingly, we found a significant decrease in acetylation and tyrosination over time (between 0 and 10 minutes), while a notable polyglutamylation of the marginal band is evident from the earliest time point (10 minutes spreading on fibrinogen) and does not decrease (Figure 4H and I).

Platelet and megakaryocyte polymodifications regulate motor protein localization to drive both proplatelet formation and platelet shape change on activation

Polyglutamylation has been reported as a means by which motor protein processivity is regulated, and like in neuronal cells, MK proplatelet formation is known to be
driven by a mechanism of dynein mediated proplatelet sliding. Similarly, the antagonistic movement of dynein and kinesin are known to maintain the marginal band in resting platelets.

In order to test if polymodification affects the spatial distribution of motors, we performed a time course of platelet spreading on fibrinogen and measured co-localization between polyglutamylated tubulin and dynein (DNAL1 - axonemal light chain 1). We observe a loss of co-localization between dynein and polyglutamylated residues upon platelet spreading (Figure 5A and B). Interestingly, axonemal dynein is also localized towards the leading edge of spread platelets (Figure 5A). This data suggests that the increased polyglutamylation of the marginal band observed on platelet spreading drives an outward movement of axonemal dynein. In order to investigate the role of axonemal dynein specifically in this process, we also stained spreading platelets for cytoplasmic dynein and observe a central distribution, suggesting an alternative role for cytoplasmic dynein in platelets (Online Supplementary Figure S6).

The loss of co-localization between polyglutamylated tubulin and dynein was confirmed on both collagen and fibrinogen spread platelets (Figure 5C and E). This spatial relationship was also observed between polyglutamylated tubulin and kinesin-1, a motor protein recently reported to be important in platelet secretion on platelet spreading (Figure 5D and F).

This data suggests that polyglutamylated tubulin is involved in localizing motor proteins during platelet activation and spreading. The actions of kinesin and dynein are known to be critical to driving platelet shape change on activation, and this work is consistent with previous reports of polyglutamylated tubulin altering the processivity of motors in axons.

We then investigated the role of these polymodifications on the distribution of motors in iPSC-MK. In proplatelet extensions axonemal dynein and kinesin-1 are both evident along the length of the proplatelet shaft (Figure 5G). β1-tubulin KO cells show no proplatelet formation, and a significant reduction in the co-localization of dynein with polyglutamylated residues when compared to WT iPSC-MK (Figure 5H and I). No significant change in the co-localization of these residues with kinesin-1 is observed between WT and KO iPSC-MK (Figure 5J).
Megakaryocyte and platelet polymodification is regulated through the expression of both modifying and reversing enzymes

We hypothesized that the expression of cell specific subsets of effecting (tubulin tyrosine ligase like [TTLL]) and reversing (cytosolic carboxypeptidase [CCP]) enzymes are required to achieve the distinctive polymodification we observe in MK and platelets. We designed a quantitative real-time polymerase chain reaction (qRT-PCR) panel to interrogate the expression of the 13 known mammalian TTLL and six CCP. We generated RNA from iPSC-MK at different stages of maturation (Figures 6A; Online Supplementary Figure S4A). Day 1 (d1) cells are representative of a pool of hematopoietic stem cells (HSC) and MK progenitors, while day 5 (d5) cells are comprised of 60% CD41/42b+ cells (Figures 6A; Online Supplementary Figure S4E). Finally, d5 cells treated with heparin to induce proplatelet formation (d5+Hep) were used to interrogate whether there is any specific upregulation of TTLL and/or CCP on proplatelet formation (Figures 6A; Online Supplementary Figure S4D).

GAPDH housekeeping controls for each of the three samples (d1, d5, d5+Hep) show equivalent amplification of the housekeeping control, while results for TTLL family proteins show a number of enzymes expressed at different levels across the maturation of these cells (Figure 6B and C). Candidate TTLL observed in the initial endpoint PCR were taken forward for quantification across replicates generated from multiple differentiations (Figure 6C and D). We find a significantly increased expression of TTLL1, TTLL2, TTLL4, and TTLL10 on proplatelet formation in cells treated with heparin (**P=0.0081, *P=0.0105, *P=0.0260, ***P=...
CCP family enzymes were also found to be expressed in maturing MK, notably CCP1, 3, 4, 5, and 6 (Figure 6E), with CCP4 and CCP6 upregulated on proplatelet production (*$P=0.0130$, **$P=0.0009$) (Figure 6F to H).

In order to investigate TTLL and CCP expression in platelets, we repeated this panel on RNA extracted from resting and CRP stimulated donor platelets. We found that none of the TTLL and CCP observed in iPSC MK were consistently expressed across donors with the exception of TTLL7, a known polyglutamylase (Figure 6I, see complete gel in the Online Supplementary Figure S10). No differences between resting and activated platelets were observed (Figure 6I). This data shows a markedly different pattern of TTLL and CCP expression in both MK and platelets, correlating with the observed differences in polymodification.
Figure 6. Continued on following page.
Figure 6. Induced pluripotent stem cell megacaryocytes and platelets differentially express TTLL and CCP enzymes to regulate polymodifications during megakaryocyte maturation and platelet production. The loss of tubulin tyrosine ligase like (TTL) TTL10 is possibly linked to a bleeding phenotype in unrelated human patients. (A) RNA was generated from induced pluripotent stem cell megacaryocytes (iPSC-MK) at different stages of terminal differentiation. Day 1 (d1) day 5 (d5) day 5 cells treated with heparin to induce proplatelet formation (d5+Hep) were used to determine whether an upregulation of these enzymes is evident on platelet production. (B) Samples were amplified with housekeeping GAPDH primers. (C) A number of TTLL family enzymes were observed, including TTLL1, 2, 3, 4, 5, 6, 7, 10, and 13. Of these, a number appeared to be upregulated in mature and proplatelet forming cells. (D and E) These samples were forward and expression was quantified over multiple differentiations using the \( \Delta\Delta^CT \) method TTLL1, 2, 4, and 10 expression was found to be significantly upregulated on treatment with heparin (\( \ast\ast\ast P=0.0004 \), \( \ast\ast P=0.0035 \), \( \ast P=0.0260 \), \( \ast\ast\ast P=0.0004 \) respectively). (F to H) A similar panel was performed on cytosolic carboxypeptidase (CCP) enzymes which reverse polymodifications, with expression of CCP1, 3, 4, 5, and 6 was observed. Statistically significant upregulation of CCP4, and CCP6 were observed on proplatelet production (\( \ast P=0.0130 \), \( \ast\ast\ast P=0.0009 \)). (I) In resting (-) and C-reactive protein (CRP) activated (+) platelets from three healthy donors TTLL7 was the only modifying enzyme found to be consistently expressed. (J) Three unrelated families were identified within the Genotyping and Phenotyping of Platelets Study (GAPP) cohort, two with frameshift truncations and one with a missense substitution (p.Pro15Argfs*38, p.Val249Glyfs*57, and p.Arg340Trp respectively, and as shown on the protein schematic of TTL10). (K) All three families present with normal platelet counts and function, but demonstrate an elevated mean platelet volume (MPV) and consistent histories of bleeding including cutaneous bruising and menorrhagia. (L) Patient A:1:1 was recalled and demonstrated abnormally large platelets on spreading on fibrinogen when imaged by widefield and single molecule localisation microscopy (tubulin staining, 10 µm scale bar, 5 µm in cropped image). (n=3, standard deviation. Two-Way ANOVA with multiple comparisons performed. Complete unedited gels found in the Online Supplementary Figures S9 and S10.)
TTLL10 variants maybe associated with moderate to severe bleeding in three unrelated families

Our qRT-PCR screen revealed that a number of TTLL and CCP are upregulated during the process of platelet production, including the polyglycylase TTLL10. Whole exome sequencing data from patients recruited to the GAPP study identified three unrelated families with rare and novel variants in the TTLL10 gene (Figure 6J; Online Supplementary Figures S12 and S13). Extensive in silico analysis was undertaken on the TTLL10 variants which were predicted as ‘uncertain significance’ using current ACMG guidelines (Online Supplementary Figures S12 and S13). Two of the three variants result in frameshifts towards the N-terminus of the protein, preceding the ATP binding region (p.Pro15Argfs*38 [novel] and p.Val249Glyfs*57 [frequency 2.15x10^-3]) (Figure 6J). The final family has a missense p.Arg340Trp variant (3.34x10^-5 frequency).

All three families report normal platelet counts, aggregation and secretion, and present with an established history of moderate to severe bleeding, including cutaneous bruising and menorrhagia (Figure 6K). Family A demonstrated a consistently high MPV (normal ranges MPF [fL] (7.83-10.5), while families B and C do not. Interestingly within family A, a second genetic variant in the TUBB1 gene, which directly affects the GFI1B promoter, was identified. Family A also demonstrates consistently high MPV (normal ranges MPF [fL] (7.83-10.5), while families B and C do not. Interestingly, one of the patients (A 1:1) was re-recruited, and on platelet spreading on fibrinogen coated coverslips we observed a marked increase in platelet area compared to controls when imaged using widefield and single molecule localisation microscopy (SMLM) (Figure 6L).

Discussion

We hypothesized that a system of polymodification (polyglutamylation and polyglycylation) targeting the glutamate rich C-terminus of β1-tubulin isoform and analogous to similar PTM demonstrated in cilia and neuronal cells, is a likely mechanism by which the interactions of β1-tubulin with key motors are regulated in both MK and platelets.

We report that mature and proplatelet forming CD42b+ iPSC-MK demonstrate both polyglutamylation and polyglycylation (polymodification). We observe a markedly different distribution of these PTM in the resting platelet, where polyglycylation is lost and polyglutamylation is partially co-localized to the marginal band. On platelet activation, we observe a marked change in the localization of polyglutamylation specific to the marginal band. In iPSC-MK with a CRISPR KO of TUBB1, we see a complete loss of proplatelet formation and lose the distinct reorganization of polyglutamylation and polyglycylation tubulin around the periphery of MK as seen in WT cells.

MK proplatelet extensions are known to be driven by a system of dynein mediated microtubule sliding, while the marginal band in a resting platelet has been shown to be maintained by the antagonistic movement of dynein and kinesin. Interestingly, polyglutamylation has been reported as a mechanism of altering motor protein processivity, with in vitro assays suggesting that polyglutamylation of β1 tubulin isoforms like TUBB1 and TUBB3 accelerates these motors. We show a significant effect of polyglutamylation in the spatial localization of dynein and kinesin, supporting in vitro assays which suggest that polyglutamylation is an accelerator of motor proteins.

We report two unrelated patient families with rare TUBB1 C-terminal variants (an R359W missense and a L361Afs*19 frameshift linked to macrothrombocytopenia). Interestingly within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed. Individuals within family A, a second genetic variant in the GH1B gene, which directly affects the TUBB1 promoter is observed.

We go on to show through the expression of these variants in Hek293T cells that each variant results in a dysfunctional β1-tubulin protein which is most likely to mirror the effects of a C-terminal truncation. The system of polymodification evidenced in iPSC-MK...
is analogous to the PTM of ciliated cells, and so we reasoned that axonemal dynein, an isof orm of the motor exclusive to axonemes, may play a role in both platelet formation and activation.\textsuperscript{59,61} We find evidence of axonemal dynein on both proplatelet extensions and at the leading edge of spreading platelets. To our knowledge this is the first evidence of a functional role of axonemal dynein outside of classical ciliated structures. In our TUBB1 KO MK, we observe a decrease in the co-localization of dynein to poly glutamyalted tubulin, suggesting that the loss of proplatelet formation observed in these cells is due to a dysregulation of the dynein-mediated microtubule sliding known to drive the elongation of the proplatelet shaft.\textsuperscript{39} The similarities between flagella and MK proplatelet extensions have been discussed previously,\textsuperscript{62} Italiano et al. observe structures similar to flagella in taxol treated MK, an idea which led to the microtubule telescoping experiment reported by Patel et al.\textsuperscript{39,40}

Our data suggests a tightly regulated, reversible system of polymodification which must be mediated by the cell specific expression of TTLL and CCP. Our expression profiles show a number of TTLL and CCP are expressed by MK, while only the polyglutamylase TTLL7 is expressed by platelets consistent with the different patterns of polymodification observed in these cells. In MK we find expression of two TTLLs known to be involved in glycylation - the initiase TTLL3 and the elongase TTLL10, with a significant increase in the expression of TTLL10 on platelet production. Our findings support a role of TTLL10 as a polyglycylase on co-expression with TTLL3 as reported by Ikegami et al. in cell lines through co-transfection experiments (Figure 7).

Finally, we report a novel gene, TTLL10, in three unrelated families with excessive bleeding. We identify three unrelated families with TTLL10 variants which result in an increase in an established history of bleeding which provides an invaluable insight to the potential role of polyglycyla tion in the context of platelet production and function. Our data shows that both TTLL3 and TTLL10 are expressed in platelet producing MK. Our patient cohort do not lose TTLL3 function, and as such the action of TTLL3 as an initiase will occupy glutamate residues which would otherwise be polyglutamylated. In these patients we likely see a loss of polyglycylation, but no coincident increase in polyglutamylation due to the normal function of the initiase (TTLL3). As polyglycylation and monoglycylation are unaffected, platelet counts (and production) are normal, however, affected individuals appear to have an increased platelet volume and bleeding, suggesting a role for the extended glycine tail in regulating platelet size, with a downstream effect on the ability of platelets to prevent bleeding.

Patel et al. describe a system by which continuous polymerization is key to the dynein-mediated sliding required for platelet production.\textsuperscript{39} This work, alongside reports of tyrosination, acetylation, and polyglutamylation in different MK models, suggests that tubulin PTM are likely part of a highly dynamic system in which polymerizing microtubules are subject to modifications which coordinate platelet production and packaging. Future work will interrogate the interplay between different PTM, and how they fit into a highly dynamic landscape of MT polymerization and function. Indeed, in our KO TUBB1 cells we do not observe a complete loss of polymodification, suggesting that compensatory mechanisms which target other isoforms of tubulin may come into play. There is likely a more extensive effect on the expression of tubulins and their interplay with other cytoskeletal proteins which should be a focus of future work. Similarly, the role of these PTs will need to be further validated in primary human CD34-derived MK.

This work supports the paradigm of a ‘tubulin code’ and the importance of microtubule patterning in healthy, and thus diseased, MK and platelets. We provide novel insights into the mechanisms by which β1-tubulin functions in these unique cells.

**Disclosures**

No conflicts of interest to disclose.

**Contributions**

AOK and NVM devised and performed experiments; AOK and NVM wrote the manuscript; AS performed homology modeling, cloning, transfection, and platelet spreading experiments; AM performed platelet spreading and analysis of patient sequencing data; PLRN performed platelet preparations and reviewed the manuscript; JAP developed and applied image analysis workflows; JSR assisted with western blotting; JY contributed to platelet preparations; all authors reviewed the manuscript.

**Acknowledgments**

We thank the families for providing samples and our clinical and laboratory colleagues for their help. The authors would like to thank the TechHub and COMPARE Core facilities at the University of Birmingham. AOK is a Wellcome funded Sir Henry Wellcome Fellow (218649/Z/19/Z). We thank Professor Steve Watson for his ongoing support and invaluable mentorship. The authors do not have any conflict of interest.

**Funding**

This work was supported by the British Heart Foundation (PG/13/36/30275; FS/13/70/30524; FS/15/18/31347; PC/16/103/32650; IG/18/2/33544). This research was funded in whole or in part by the Wellcome Trust (218649/Z/19/Z).

**References**

10. Wu HY, Wei P, Morgan JL. Role of cytosolic...
11. Vogel F, Hansen G, Fontenot G, Read R. Tubulin tyrosine ligase-I deficiency results in chronic rhinosinusitis and abnor-
14. Sadoul K. New explanations for old observa-
15. Poulter Natalie S, Thomas SG. Cytoskeletal interaction in TUBB1 associated with thrombocy-
16. Machlus KR, Italiano JE. The incredible jour-
tal macrothrombocytopenia affecting micro-
tubule assembly. Blood. 2009;113(2):458-
465.
restricted and divergent beta-tubulin iso-
tal macrothrombocytopenia affecting micro-
tubule assembly. Blood. 2009;113(2):458-
461.
19. Kunishima S, Nishimura S, Suzuki H, Inmaizumi M, Saito H. TUBB1 mutation dis-
rupting microtubule assembly impairs pro-
20. Fiore M, Goulas C, Fillos X. A new muta-
tion in TUBB1 associated with thrombocy-
topenia confirms that C-terminal part of b1-
21. Natarajan K, Gadadhar S, Souprhon J, Magiera MM, Janke Carsten. Molecular interaction between tubulin tails and glutamy-
26. Guex N, Peitsch MC. Automated comparative protein structure modeling with SWISS-MODEL and Swiss-
30. Johnson B, Lowe GC, Futterer J, et al. Whole exome sequencing identifies genetic variants in inherited thrombocytopathy with second-
32. Richards S, Azza N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recom-
35. Ikegami K, Mukai M, Tsuchida J, Heier RL, Davidson MW, Piston DW. Photocconversion in orange and red fluores-
cent proteins. Nat Methods. 2009;6(5):355-
358.
37. Khan AO, White CW, Pike JA, et al. Optimised insert design for improved single-
39. Khan AO, White CW, Pike JA, et al. Optimised insert design for improved single-
40. Khan AO, Simms VA, Smith CW, et al. An adaptable analysis workflow for characteri-
zation of platelet spreading and morphol-